Johnson & Johnson’s Spravato now available as a standalone depression therapyJanuary 21, 2025 FDA approves Johnson & Johnson’s Spravato as a standalone therapy, marking a breakthrough for treatment-resistant depression and offering rapid relief to patients with unmet medical needs.
